Tag Archives: NEJM

September, 2018

July, 2018

April, 2018

October, 2017

  • 6 October

    Bluebird Gene Therapy Halts Progression of Cerebral Adrenoleukodystrophy

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from an initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating Lenti-D™ investigational …

May, 2017

March, 2017

March, 2015